Verily’s Pivot: From Disease Management App to Personalized Healthcare Solutions

Alphabet’s Health Company, Verily, Entering the GLP-1 Obesity Market

Verily, a health tech spinout owned by Google, is undergoing another pivot as it transitions from its chronic disease management app Onduo to a new product called Lightpath Metabolic. Over the next year and a half, Onduo will be phased out to make way for this new product, which is expected to launch in 2026. Unlike Onduo, which focused solely on managing type 1 and type 2 diabetes and hypertension, Lightpath Metabolic will offer GLP-1 drug prescriptions and utilize artificial intelligence and data from devices like continuous glucose monitoring devices to personalize care for users.

Despite these changes, Verily’s shift towards an app that offers AI assistance and telehealth prescriptions marks a departure from its original vision of “defeating Mother Nature.” The company, founded on ambitious ideas like cancer-detecting wristbands, has struggled to find its direction over the past nine years. Projects like a contact-lens continuous glucose monitor have been abandoned, and turnover among employees and executives has been a persistent issue for the company.

However, with the introduction of Lightpath Metabolic, Verily continues to adapt its offerings to meet the changing needs of users in the healthcare space. For more in-depth analysis of the technologies disrupting healthcare, readers can access exclusive content on STAT+ by subscribing for unlimited access to award-winning journalism and exclusive events.

Leave a Reply